FIELD: medicine.
SUBSTANCE: correcting pathological processes caused by high cholesterolesterase activity is ensured by using protatran 4-chlor-2-methylphenoxyacetate (chlorcresacin).
EFFECT: using this compound enables increasing the cholesterol resistance of the vascular system involved into a developing atherosclerotic process.
2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTANCE REDUCING CHOLESTEROL ESTERASE ACTIVITY | 2014 |
|
RU2540518C1 |
| APPLICATION OF PROTATRAN 4-CHLORO-2-METHYLPHENOXYACETATE FOR EXHAUSTING OF MONONUCLEAR CELLS BASIC (ALKALINE) PHOSPHOLIPASE a2 TOTAL ACTIVITY | 2016 |
|
RU2619860C1 |
| AGENT TO DECREASE CHOLESTEROL ESTERASE ACTIVITY | 2010 |
|
RU2444357C1 |
| USE OF 1-(HERMATRANE-1-YL)-1-OXYETHYLAMINE FOR INHIBITING TOTAL ACTIVITY OF BASIC (ALKALINE) PHOSPHOLIPASE A2 OF MONONUCLEAR CELLS | 2020 |
|
RU2732883C1 |
| USE OF BIS(Μ-TARTRATO)DI(Μ-HYDROXO)GERMANATE (IV) TRIETHANOLAMMONIUM FOR INHIBITING TOTAL ACTIVITY OF BASIC (ALKALINE) PHOSPHOLIPASE A2 OF MONONUCLEAR CELLS | 2020 |
|
RU2733166C1 |
| METHOD OF INHIBITING TOTAL ACTIVITY OF BASIC (ALKALINE) PHOSPHOLIPASE A2 OF MONONUCLEAR CELLS USING BIS(Μ-TARTRATO)DI(Μ-HYDROXO)GERMANATE (IV) TRIETHANOLAMMONIUM | 2020 |
|
RU2732880C1 |
| METHOD FOR SUPPRESSING TOTAL ACTIVITY OF BASIC (ALKALINE) PHOSPHOLIPASE A2 OF MONONUCLEAR CELLS USING 1-(HERMATRANE-1-YL)-1-OXYETHYLAMINE | 2020 |
|
RU2732881C1 |
| METHOD FOR CORRECTING ATHEROGENESIS EXPERIMENTALLY USING 1-HYDROXYGERMATRANE | 2020 |
|
RU2741229C1 |
| USING COMPLEX OF TRIS-(2-HYDROXYETHYL)AMINE AND ZINC BIS-(2-METHYLPHENOXYACETATE) (CINKATRAN) AS AGENT SUPPRESSING TOTAL ACTIVITY OF BASIC (ALKALINE) MONONUCLEAR PHOSPHOLIPASE A2 | 2014 |
|
RU2546537C1 |
| USE OF 1-(GERMATRAN-1-YL)-1-HYDROXYETHYLAMINE FOR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROSIS IN THE EXPERIMENT | 2020 |
|
RU2746321C1 |
